YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT

Other Chinese Firms Build Presence In Field

 
• By Xu Hu
  
Gene editing tool
YolTech Therapeutics' first-in-class in vivo gene editing therapy, YOLT-204, in transfusion dependent β-thalassemia recently entered clinical trial. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Focus On Asia